Our antibodies are used worldwide Today we share insights into a new biomarker for glioma, the metastatic process in colorectal cancer, and the effect of ginseng metabolites on cancer cell proliferation. Read on!
1) Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease
Genes specifically expressed by tumor cells, like tenascin C (TNC), can shape the brain parenchyma. TNC increases the stiffness of the extracellular matrix, which compromises vascular integrity and induces hypoxia. In addition, TNC promotes glioma invasion and angiogenesis resulting in tumor progression and poor prognosis.
In most healthy adult brains, TNC is undetectable but rapidly induced by pro-inflammatory cytokines in various pathological conditions, including gliomas.
Using our anti-TNC (HPA004823) polyclonal antibody, this study analyzed TNC expression on a large cohort of pediatric glioma tissue specimens. The results show that TNC overexpression is also clinically detectable in pediatric high-grade and diffuse midline pontine glioma (DIPG) and may significantly contribute to tumor biology.
TNC endogenous expression levels in pediatric glioma tissue are grade-dependent but higher in tumors harboring the H3K27 M mutation. In conclusion, TNC may contribute to DIPG tumor phenotype and serve as a clinically detectable biomarker for tumor progression.
Qi, J., Esfahani, D.R., Huang, T. et al. Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease. acta neuropathol commun 7, 75 (2019).